Featured Multi-Omics & Sequencing Solutions
Integrating genomics, transcriptomics, and metabolomics is crucial for comprehensive protein identification and functional proteomics. Below are our four core platforms widely utilized in biomedical and translational research in Switzerland.
Biomarker Technologies (BMKGene)
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform.
We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale. By bridging the gap between gene sequence and functional protein expression, BMKGene empowers researchers to accelerate discoveries in human health, clinical diagnostics, and agricultural biotechnology.
🧬 Innovation Highlights
- 16+ Years of high-throughput sequencing expertise.
- 60+ National Patents and 200+ software copyrights.
- BMKMANU S3000 proprietary spatial transcriptome platform.
- Global network serving researchers in 84 regions.
- Seamless integration of transcriptomics with downstream protein identification.
The Landscape of Protein Identification & Proteomics in Switzerland
Switzerland has solidified its position as one of the world's most advanced hubs for biotechnology, pharmaceuticals, and life sciences. The Swiss market for protein identification and proteomics is driven by a unique blend of world-class academic institutions, global pharmaceutical giants, and a highly specialized biotech ecosystem.
The Swiss Biotech Valley
Regions around Basel, Zurich, and the Lake Geneva area (Lausanne and Geneva) form a dense cluster of life science companies. Global giants such as Roche and Novartis, alongside hundreds of specialized biotech firms, rely heavily on advanced protein identification services to drive their drug discovery pipelines and target validation.
Academic Excellence
Institutions like ETH Zurich, EPFL, and the University of Basel are pioneers in mass spectrometry and structural biology. Swiss researchers are at the forefront of combining high-throughput genomics with quantitative proteomics (proteogenomics) to map the complete cellular landscape, identifying novel biomarkers for complex diseases.
Infrastructure & Quality
Swiss biotechnology is synonymous with precision and quality. Local research labs and contract research organizations (CROs) enforce strict regulatory standards. This demand for extreme accuracy has accelerated the adoption of automated sample preparation, high-resolution mass spectrometry, and advanced bioinformatics platforms.
Key Industry Trends in Proteogenomics & Protein Identification
The field of protein identification is undergoing a significant paradigm shift. Historically, proteomics (the study of proteins) and genomics (the study of genes) operated in silos. Today, Swiss research institutes and commercial enterprises are driving the adoption of proteogenomics—the integrative analysis of genomic, transcriptomic, and proteomic data.
One of the most prominent trends is the rise of single-cell proteomics. Understanding protein expression at the single-cell level is critical for oncology research, where tumor heterogeneity often dictates treatment success. By combining single-cell RNA sequencing with mass cytometry or high-plex spatial profiling, scientists can verify if transcription levels accurately translate to functional protein levels.
Furthermore, the integration of Artificial Intelligence (AI) and machine learning has revolutionized protein structure prediction and identification. AI models analyze massive datasets generated by next-generation sequencing (NGS) and mass spectrometry, allowing for rapid, high-confidence identification of post-translational modifications (PTMs) and novel protein isoforms that were previously undetectable.
Emerging Methodologies in Switzerland
1. Spatial Proteogenomics
Mapping RNA and protein expression simultaneously directly within the tissue microenvironment using platforms like BMKMANU S3000.
2. High-Throughput Mass Spectrometry (MS)
Using advanced QTOF and Orbitrap platforms to identify thousands of proteins in a single run, reducing processing times for clinical cohorts.
3. Multi-Omics Data Integration
Combining metabolomics, transcriptomics, and genomics through cloud-based bioinformatics (BMKCloud) to identify key biomarkers.
Localized Application Scenarios in Switzerland
How are Swiss industries and academic laboratories applying these advanced multi-omics and protein identification services? Here are the primary localized scenarios driving scientific innovation today:
1 Precision Medicine & Oncology in Swiss Clinics
At leading Swiss clinical centers, spatial transcriptomics and protein identification are combined to analyze patient tumor biopsies. This allows oncologists to discover unique protein biomarkers associated with immunotherapy resistance, mapping precisely where these proteins are expressed within the tumor microenvironment to customize patient treatments.
2 Swiss Agro-Biotech & Food Science
Switzerland's agricultural research centers (such as Agroscope) and global food science corporations (like Nestlé Research) utilize metabolomics and transcriptomics to study plant-microbe interactions, crop resilience, and food safety. Identifying specific proteins in crops helps breed varieties that are resistant to disease and climate stressors without genetic modification.
3 Biopharmaceutical Development & Quality Control
In the Basel biotech cluster, developing therapeutic antibodies and recombinant proteins requires strict monitoring of host cell proteins (HCPs) and post-translational modifications. High-throughput DNBSEQ and PacBio sequencing, combined with downstream mass spectrometry, ensure the safety, purity, and efficacy of biologic drugs.
4 Environmental Metagenomics & Microbiome Research
Swiss alpine ecosystems and lakes serve as natural laboratories. Researchers use prokaryotic RNA sequencing and metagenomics to identify functional proteins expressed by microbial communities, helping monitor environmental health, soil quality, and water safety across the Swiss cantons.
Our Platforms & Automated Molecular Laboratory
To deliver industry-leading data accuracy and speed, BMKGene utilizes the most advanced sequencing and mass spectrometry instruments. Our state-of-the-art laboratory spans over 20,000 square feet, facilitating high-throughput molecular analysis.
Advanced Instruments
PacBio: Sequel II, Sequel, RSII
Nanopore: PromethION P48, GridION X5 MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina: NovaSeq
BGI: DNBSEQ-G400, DNBSEQ-T7
Bionano: Irys system
Mass Spec: Waters XEVO G2-XS QTOF, QTRAP 6500+
Over 20,000 Sq. Ft. Lab
Our facilities feature standard laboratories for sample extraction, library construction, clean rooms, and sequencing labs. We run standard procedures under strict SOPs to guarantee reproducibility.
Bioinformatic Platform
BMKCloud: Our self-developed online bioinformatic analysis platform operates with 4,260 computing cores, 41,104 memory, 3 PB total storage, and peak power over 121,708.8 Gflop/s.
Fully Automated Platform for Next-generation sequencing--Brilliant Lab 1000
Biomarker Technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to the high-throughput NGS library construction service.
Brilliant Lab 1000 (BL1000) Advantages
By utilizing automated robotics, BL1000 minimizes human error, standardizes processing pipelines, and significantly decreases turnaround times. BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.
Enterprise Qualifications & Certifications
Quality, compliance, and scientific rigor are at the core of our operations. BMKGene is certified by international standards bodies and possesses numerous patents and software copyrights for advanced bioinformatics analysis.
Complete Multi-Omics & Sequencing Product Portfolio
Explore our complete suite of high-throughput sequencing and multi-omics solutions. Designed to support advanced biomarker discovery, transcriptomics, metabolomics, and protein identification workflows globally.
Whole Transcriptome Sequencing - Illumina
Learn More
Metabolomics
Learn More
DNBSEQ pre-made libraries
Learn More
Full-length mRNA sequencing -PacBio
Learn More
Prokaryotic RNA Sequencing
Learn More
circ-RNA
Learn More
Small RNA Sequencing-Illumina
Learn More
Hi-C based Chromatin Interaction
Learn MoreAccelerate Your Proteomics & Transcriptomics Research
Need a customized experimental design or price list for your research in Switzerland? Contact our technical experts today. We respond to all inquiries within 24 hours.
Inquiry Now
